Summary: An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.

Top Publications

  1. Fanta C. Asthma. N Engl J Med. 2009;360:1002-14 pubmed publisher
  2. Rivero A, Liang J. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis. Ann Otol Rhinol Laryngol. 2017;126:739-747 pubmed publisher
    ..Meta-analysis was performed on 5 studies: Anti-IL5 therapy (mepolizumab/reslizumab) and anti-IgE therapy (omalizumab) demonstrated a standard mean difference of NPS improvement of -0.66 (95% CI, -1.24 to -0.08) and -0...
  3. Schaefer P. Acute and Chronic Urticaria: Evaluation and Treatment. Am Fam Physician. 2017;95:717-724 pubmed
    ..In refractory chronic urticaria, patients can be referred to subspecialists for additional treatments, such as omalizumab or cyclosporine...
  4. Nadeau K, Schneider L, Hoyte L, Borras I, Umetsu D. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol. 2011;127:1622-4 pubmed publisher
  5. Douglass J, Carroll K, Voskamp A, Bourke P, Wei A, O Hehir R. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy. 2010;65:926-7 pubmed publisher
  6. Asero R. Disappearance of severe oral allergy syndrome following omalizumab treatment. Eur Ann Allergy Clin Immunol. 2017;49:143-144 pubmed
    ..first case of disappearance of apple-induced oral allergy syndrome in a birch pollen-allergic patient following omalizumab treatment is reported...
  7. Yalcin A, Genç G, Celik B, Gumuslu S. Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200. Clin Lab. 2014;60:523-4 pubmed
    ..regimens (systemic steroids, daily cyclophosphamide) for BP but responded rapidly to systemic anti-IgE (omalizumab). Our patient is a 28 year-old white male...
  8. Azofra J, Diaz C, Antepara I, Jauregui I, Soriano A, Ferrer M. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema. Ann Allergy Asthma Immunol. 2015;114:418-9.e1 pubmed publisher
  9. Matito A, Blázquez Goñi C, Morgado J, Alvarez Twose I, Mollejo M, Sánchez Muñoz L, et al. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol. 2013;111:425-6 pubmed publisher

More Information


  1. Busse W, Spector S, Rosén K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132:485-6.e11 pubmed publisher
  2. Dunn N, Neff L, Maurer D. A stepwise approach to pediatric asthma. J Fam Pract. 2017;66:280-286 pubmed
    ..Two guidelines and several recent studies are available to guide your care. This review--with handy figure--puts it all at your fingertips. ..
  3. London V, Kim G, Fairley J, Woodley D. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol. 2012;148:1241-3 pubmed publisher
  4. Kontou Fili K, Filis C. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy. 2009;64:1384-5 pubmed publisher
  5. Sampson H, Leung D, Burks A, Lack G, Bahna S, Jones S, et al. A phase II, randomized, double?blind, parallel?group, placebo?controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127:1309-10.e1 pubmed publisher
  6. Kitsioulis N, Xepapadaki P, Roussaki Schulze A, Papadopoulos N, Zafiriou E. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria. Int Arch Allergy Immunol. 2017;172:161-166 pubmed publisher
    Nonsedating antihistamines are the treatment of choice for chronic spontaneous urticaria (CSU), while omalizumab and immunosuppressants have also been approved as an add-on treatment...
  7. Schroeder J, Bieneman A. Activation of Human Basophils by A549 Lung Epithelial Cells Reveals a Novel IgE-Dependent Response Independent of Allergen. J Immunol. 2017;199:855-865 pubmed publisher
    ..Ig stripping combined with passive sensitization ± omalizumab showed a dependency for basophil-bound IgE, substantiated by a requirement for cell-to-cell contact, aggregation,..
  8. Kibsgaard L, Skjold T, Deleuran M, Vestergaard C. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis. Acta Derm Venereol. 2014;94:363-4 pubmed publisher
  9. Vitale C, Maglio A, Pelaia C, Vatrella A. Long-term treatment in pediatric asthma: an update on chemical pharmacotherapy. Expert Opin Pharmacother. 2017;18:667-676 pubmed publisher
    ..More recent strategies based on the use of a biological drug such as omalizumab, which is a monoclonal antibody directed against immunoglobulin E (IgE), can be considered in selected patients ..
  10. De Schryver E, Derycke L, Calus L, Holtappels G, Hellings P, Van Zele T, et al. The effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps. Rhinology. 2017;55:152-160 pubmed publisher
    ..The effect on nasal and serum periostin levels is however yet unknown. We aimed to evaluate the effect of omalizumab, mepolizumab, methylprednisolone and doxycycline on nasal and systemic periostin expression...
  11. Chipps B, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler S, et al. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139:1431-1444 pubmed publisher
    ..b>Omalizumab, an anti-IgE mAb, is the first targeted biologic therapeutic approved for the treatment of moderate-to-severe ..
  12. Lambert N, Guiddir T, Amat F, Just J. Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Pediatr Allergy Immunol. 2014;25:829-32 pubmed publisher
  13. Kallieri M, Papaioannou A, Papathanasiou E, Ntontsi P, Papiris S, Loukides S. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study. Postgrad Med. 2017;129:598-604 pubmed publisher
    b>Omalizumab is a recombinant humanized IgG1 monoclonal anti-IgE antibody, used for the treatment of severe refractory allergic asthma. However, not all patients with IgE levels within the limits of administration, respond to treatment...
  14. Esquivel A, Busse W, Calatroni A, Togias A, Grindle K, Bochkov Y, et al. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. Am J Respir Crit Care Med. 2017;196:985-992 pubmed publisher
    ..Allergic inflammation has been linked to increased susceptibility to viral illnesses, but it is unclear whether this association is causal...
  15. Garcia G, Magnan A, Chiron R, Contin Bordes C, Berger P, Taillé C, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013;144:411-419 pubmed publisher
    ..b>Omalizumab, an anti-IgE monoclonal antibody, is reported to significantly benefit a subset of patients with severe, ..
  16. Vigl B, Salhat N, Parth M, Pankevych H, Mairhofer A, Bartl S, et al. Quantitative in vitro and in vivo models to assess human IgE B cell receptor crosslinking by IgE and EMPD IgE targeting antibodies. J Immunol Methods. 2017;449:28-36 pubmed publisher
    Targeting plasma IgE by therapeutic mABs like Omalizumab (Xolair®) is current clinical practice for severe allergic conditions or other IgE related diseases like chronic urticaria...
  17. Bhutani M, Yang W, Hebert J, de Takacsy F, Stril J. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study. PLoS ONE. 2017;12:e0183869 pubmed publisher
    b>Omalizumab is a non-steroidal medication indicated for the treatment of poorly controlled moderate-to-severe allergic asthmatics. This observational study examines the "real world" effectiveness of omalizumab in this population...
  18. Davies A, Allan E, Keeble A, Delgado J, Cossins B, Mitropoulou A, et al. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J Biol Chem. 2017;292:9975-9987 pubmed publisher
    Immunoglobulin E and its interactions with receptors FcϵRI and CD23 play a central role in allergic disease. Omalizumab, a clinically approved therapeutic antibody, inhibits the interaction between IgE and FcϵRI, preventing mast ..
  19. Pitt T, Cisneros N, Kalicinsky C, Becker A. Successful treatment of idiopathic anaphylaxis in an adolescent. J Allergy Clin Immunol. 2010;126:415-6; author reply 416 pubmed publisher
  20. Frischmeyer Guerrerio P, Masilamani M, Gu W, Brittain E, Wood R, Kim J, et al. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2017;140:1043-1053.e8 pubmed publisher
    In our recent clinical trial, the addition of omalizumab to oral immunotherapy (OIT) for milk allergy improved safety, but no significant clinical benefit was detected...
  21. Goldstein S, Gabriel S, Kianifard F, Ortiz B, Skoner D. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials. Ann Allergy Asthma Immunol. 2017;118:500-504 pubmed publisher
    Adults and adolescents were included in 3 phase 3 omalizumab trials in chronic idiopathic urticaria (CIU): ASTERIA I, ASTERIA II, and GLACIAL...
  22. Bartuzi Z, Bodzenta Łukaszyk A, Kuna P, Kuprys Lipinska I, Nizankowska Mogilnicka E, Samoliński B. The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab. Pneumonol Alergol Pol. 2015;83:335-8 pubmed publisher
  23. Rottem M, Segal R, Kivity S, Shamshines L, Graif Y, Shalit M, et al. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience. Isr Med Assoc J. 2014;16:487-90 pubmed
    ..b>Omalizumab, anti-immunoglobulin-E humanized monclonal antibody, was recently shown to be effective in treating resistant ..
  24. Dufour C, Souillet A, Chanelière C, Jouen F, Bodemer C, Jullien D, et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol. 2012;166:1140-2 pubmed publisher
  25. Ghazanfar M, Sand C, Thomsen S. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Br J Dermatol. 2016;175:404-6 pubmed publisher
  26. Kai A, Flohr C, Grattan C. Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis. Clin Exp Dermatol. 2014;39:651-2 pubmed publisher
  27. Lang D. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema. Ann Allergy Asthma Immunol. 2014;112:276-9 pubmed publisher
  28. von Websky A, Reich K, Steinkraus V, Breuer K. Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab. J Dtsch Dermatol Ges. 2013;11:677-8 pubmed publisher
  29. Warrier P, Casale T. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol. 2009;102:257-8 pubmed publisher
  30. Vennera M, Picado C, Mullol J, Alobid I, Bernal Sprekelsen M. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66:824-5 pubmed publisher
  31. Fairley J, Baum C, Brandt D, Messingham K. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123:704-5 pubmed publisher
  32. Yalcin A, Gorczynski R, Cilli A, Strauss L. Omalizumab (anti-IgE) therapy increases blood glucose levels in severe persistent allergic asthma patients with diabetes mellitus: 18 month follow-up. Clin Lab. 2014;60:1561-4 pubmed
    Therapeutic anti-IgE antibodies (Xolair, omalizumab) able to reduce free IgE levels and to block the binding of IgE to Fcepsilon RI without cross-linking IgE and triggering degranulation of IgE-sensitised cells have been developed...